467456-99-1Relevant articles and documents
AUTOTAXIN INHIBITORS AND USES THEREOF
-
Paragraph 00324; 00325, (2016/12/22)
Described herein are methods and compositions for the treatment of conditions, diseases, or disorders associated with autotaxin activity. The methods and compositions disclosed herein include the use of at least one autotaxin inhibitor compound.
AUTOTAXIN INHIBITOR COMPOUNDS
-
Paragraph 00601, (2015/04/15)
Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with autotaxin activity.
AUTOTAXIN INHIBITOR COMPOUNDS
-
Paragraph 00339, (2015/06/08)
Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorde
Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor
-
Paragraph 0256; 0278, (2015/06/16)
Described herein are methods and compositions for treatment or prevention of metabolic disorder(s) in an individual. The methods and compositions disclosed herein include the use of at least one autotaxin inhibitor compound.
N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR
-
Paragraph 0268, (2016/01/25)
The present invention relates to the use compounds of formula I which are antagonists of the 5-HT 6 receptor, for treating a cognitive disorder selected from the group consisting of age-related cognitive decline, mild cognitive impairment and dementia